[go: up one dir, main page]

NO317426B1 - Nye forbindelser og sammensetninger,og anvendelse av disse nye forbindelser for fremstillling av et legemiddel for forebyggelse eller behandling av diabetes mellitus svekket glukosetoleranse hyperlipedemi, forsterkning av insulinsensitivitet og forbedring av insulinresistens - Google Patents

Nye forbindelser og sammensetninger,og anvendelse av disse nye forbindelser for fremstillling av et legemiddel for forebyggelse eller behandling av diabetes mellitus svekket glukosetoleranse hyperlipedemi, forsterkning av insulinsensitivitet og forbedring av insulinresistens Download PDF

Info

Publication number
NO317426B1
NO317426B1 NO20005531A NO20005531A NO317426B1 NO 317426 B1 NO317426 B1 NO 317426B1 NO 20005531 A NO20005531 A NO 20005531A NO 20005531 A NO20005531 A NO 20005531A NO 317426 B1 NO317426 B1 NO 317426B1
Authority
NO
Norway
Prior art keywords
group
carbon atoms
ethyl acetate
added
methyl
Prior art date
Application number
NO20005531A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005531L (no
NO20005531D0 (no
Inventor
Hiroyuki Odaka
Hiroshi Imoto
Hiroyuki Kimura
Junichi Sakamoto
Yu Momose
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20005531D0 publication Critical patent/NO20005531D0/no
Publication of NO20005531L publication Critical patent/NO20005531L/no
Publication of NO317426B1 publication Critical patent/NO317426B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20005531A 1998-05-11 2000-11-02 Nye forbindelser og sammensetninger,og anvendelse av disse nye forbindelser for fremstillling av et legemiddel for forebyggelse eller behandling av diabetes mellitus svekket glukosetoleranse hyperlipedemi, forsterkning av insulinsensitivitet og forbedring av insulinresistens NO317426B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP12792298 1998-05-11
JP12792198 1998-05-11
PCT/JP1999/002407 WO1999058510A1 (en) 1998-05-11 1999-05-10 Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

Publications (3)

Publication Number Publication Date
NO20005531D0 NO20005531D0 (no) 2000-11-02
NO20005531L NO20005531L (no) 2001-01-05
NO317426B1 true NO317426B1 (no) 2004-10-25

Family

ID=26463748

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005531A NO317426B1 (no) 1998-05-11 2000-11-02 Nye forbindelser og sammensetninger,og anvendelse av disse nye forbindelser for fremstillling av et legemiddel for forebyggelse eller behandling av diabetes mellitus svekket glukosetoleranse hyperlipedemi, forsterkning av insulinsensitivitet og forbedring av insulinresistens

Country Status (26)

Country Link
US (3) US6251926B1 (sk)
EP (2) EP1428531A1 (sk)
JP (1) JP2000198772A (sk)
KR (1) KR100388120B1 (sk)
CN (1) CN1148361C (sk)
AR (1) AR029876A1 (sk)
AT (1) ATE272625T1 (sk)
AU (1) AU766831B2 (sk)
BR (1) BR9910371A (sk)
CA (1) CA2331879A1 (sk)
CO (1) CO5040066A1 (sk)
DE (1) DE69919156T2 (sk)
ES (1) ES2226377T3 (sk)
HU (1) HUP0103714A3 (sk)
ID (1) ID28699A (sk)
IL (1) IL139470A0 (sk)
LV (1) LV12606B (sk)
MY (1) MY123337A (sk)
NO (1) NO317426B1 (sk)
NZ (1) NZ508066A (sk)
PE (1) PE20000625A1 (sk)
PL (1) PL344002A1 (sk)
PT (1) PT1077957E (sk)
RU (1) RU2213738C2 (sk)
SK (1) SK16412000A3 (sk)
WO (1) WO1999058510A1 (sk)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766831B2 (en) * 1998-05-11 2003-10-23 Takeda Pharmaceutical Company Limited Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
DK1206457T3 (da) * 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
DE19948126A1 (de) * 1999-10-06 2001-04-12 Max Delbrueck Centrum Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock
US6518435B1 (en) 1999-10-29 2003-02-11 Takeda Chemical Industries, Ltd. Process for the preparation of oxyiminoalkanoic acid derivatives
AR031078A1 (es) 1999-10-29 2003-09-10 Takeda Pharmaceutical Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima.
CN1260227C (zh) 1999-11-10 2006-06-21 武田药品工业株式会社 含氮的五元杂环化合物
WO2001034579A1 (en) * 1999-11-10 2001-05-17 Takeda Chemical Industries, Ltd. Alkoxyiminoalkanoic acid derivatives
PL356745A1 (en) * 1999-11-10 2004-06-28 Takeda Chemical Industries, Ltd Body weight gain inhibitors
EP1277730A4 (en) * 2000-03-28 2005-03-16 HEMMER OF NEOVASCULARIZATION
AU2001277723A1 (en) * 2000-08-11 2002-02-25 Nippon Chemiphar Co., Ltd. Ppardelta activators
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en) * 2000-08-22 2006-04-27 Malcolm Allison Combination
DE60139025D1 (de) * 2000-12-28 2009-07-30 Takeda Pharmaceutical Alkansäurederivate, verfahren zu deren herstellung und deren verwendung
WO2002076959A1 (en) * 2001-03-23 2002-10-03 Takeda Chemical Industries, Ltd. Five-membered heterocyclic alkanoic acid derivative
WO2002087580A1 (en) * 2001-04-25 2002-11-07 Takeda Chemical Industries, Ltd. Abc expression promoters
JP2005516968A (ja) * 2001-12-29 2005-06-09 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１化合物と糖尿病後期合併症モジュレーターの組み合わせ使用
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
WO2004037168A2 (en) * 2002-10-18 2004-05-06 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
JP2006509504A (ja) * 2002-12-11 2006-03-23 ユニバーシティー オブ マサチューセッツ 脂肪細胞へのｓｉＲＮＡの導入方法
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
AU2003292775A1 (en) * 2002-12-27 2004-07-29 Takeda Pharmaceutical Company Limited Body weight gain inhibitor
WO2005027967A1 (ja) * 2003-09-17 2005-03-31 Kaname Kawasugi 医薬組成物
CA2553572A1 (en) * 2004-02-24 2005-09-09 Irm Llc Immunosuppressant compounds and compositions
CN1972715A (zh) * 2004-03-29 2007-05-30 三共株式会社 含有胰岛素抵抗改善剂的糖尿病治疗剂
EP1731505B1 (en) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
EP1790338A4 (en) * 2004-09-13 2007-12-12 Santen Pharmaceutical Co Ltd THERAPEUTIC AGENT FOR KERATOCONJUNTIVA DISEASES
US7556933B2 (en) * 2004-10-01 2009-07-07 Luminultra Technologies Ltd. Reagent system and process for adenosine triphosphate monitoring
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
EP1876179B1 (en) 2005-04-28 2015-03-25 Takeda Pharmaceutical Company Limited Thienopyrimidone compounds
US7781469B2 (en) 2005-05-27 2010-08-24 Shionogi & Co., Ltd. Arylacetate derivatives having isoxazole skeleton
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
US7491414B2 (en) * 2005-10-12 2009-02-17 Gaia Herbs, Inc. Anti-inflammatory substances extracted from Echinacea
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
EP2266983B1 (en) 2008-04-16 2013-06-05 Takeda Pharmaceutical Company Limited Nitrogenated 5-membered heterocyclic compound
US20110230428A1 (en) * 2008-07-22 2011-09-22 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JPWO2010016552A1 (ja) 2008-08-07 2012-01-26 武田薬品工業株式会社 過敏性腸症候群治療薬
EP2374007A2 (en) 2008-12-04 2011-10-12 IKFE GmbH Biomarkers for atherosclerosis
AU2009325962A1 (en) 2008-12-11 2011-07-28 Ikfe Institut Fur Klinische Forschung Und Entwicklung Gmbh Biomarkers for insulin sensitizer drug response
EP2382467A1 (en) 2008-12-30 2011-11-02 IKFE GmbH Biomarkers for adipose tissue activity
US20100210541A1 (en) 2009-01-07 2010-08-19 Andreas Pfuetzner Biomarkers for Appetite Regulation
CN102875548A (zh) * 2011-07-14 2013-01-16 中国科学院大连化学物理研究所 一类基于肟的通过[2+2+2]环加成合成吡啶衍生物的方法
CN103827095A (zh) 2011-08-30 2014-05-28 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
PH12017502049A1 (en) 2011-08-30 2018-08-29 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
WO2014007228A1 (ja) 2012-07-03 2014-01-09 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
PT3053916T (pt) 2013-09-30 2019-03-26 Ono Pharmaceutical Co Composto com atividade agonista do recetor da somatostatina e utiliza ao farmaceutica do mesmo
US20160083380A1 (en) * 2013-12-16 2016-03-24 Cadila Healthcare Limited Oximino derivatives for the treatment of dyslipidemia
PE20170770A1 (es) 2014-07-17 2017-07-04 Chdi Foundation Inc Metodos y composiciones para tratar trastornos relacionados con vih
FR3042903B1 (fr) * 2015-10-21 2017-12-08 Commissariat Energie Atomique Utilisation d'acides hydroxyiminoalcanoiques comme agents anti-nitreux dans des operations de desextraction reductrice du plutonium
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
RU2019124888A (ru) 2017-02-08 2021-03-10 Оно Фармасьютикал Ко., Лтд. Соединение, имеющее агонистическую активность в отношении рецептора соматостатина, и его фармацевтическое применение
ES3035683T3 (en) 2019-02-21 2025-09-08 Steelcase Inc Body support member
US11357329B2 (en) 2019-12-13 2022-06-14 Steelcase Inc. Body support assembly and methods for the use and assembly thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177578B (en) 1976-08-27 1981-11-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing new 0-/3-amino-2-hydroxy-propyl/-amidoxime derivatives
JPS5849382A (ja) 1981-09-18 1983-03-23 Kyowa Hakko Kogyo Co Ltd β−ラクタム化合物
JPS59167576A (ja) 1983-03-15 1984-09-21 Kyowa Hakko Kogyo Co Ltd β−ラクタム化合物
JPS6277391A (ja) 1984-12-21 1987-04-09 Mochida Pharmaceut Co Ltd セフアロスポリン誘導体、その製法およびそれらを有効成分とする抗菌剤
JPS62158290A (ja) * 1985-12-28 1987-07-14 Banyu Pharmaceut Co Ltd 新規セフアロスポリン誘導体
US4698338A (en) * 1986-02-19 1987-10-06 Eli Lilly And Company 7[2-(2-aminothiazol-4-yl)-2-benzyloximino]acetamido-3[4-alkyl-5-oxo-6-hydroxy-3,4-dihydro-1,2,4-triazin-3-yl]thiomethyl cephalosporins
US5750532A (en) * 1986-12-10 1998-05-12 Schering Corporation Pharmaceutically active compounds
JPH0277391A (ja) 1988-09-14 1990-03-16 Suzuki Motor Co Ltd 水ジェット推進船のビルジ水排水装置
DE68905765T3 (de) 1988-11-21 1998-03-26 Zeneca Ltd Fungizide.
EP0400805A1 (en) 1989-04-25 1990-12-05 Toshiyasu Ishimaru Cephalosporin compounds and their use
JPH03115272A (ja) * 1989-10-19 1991-05-16 Banyu Pharmaceut Co Ltd マンデル酸誘導体およびその製法
IE990233A1 (en) * 1990-06-18 2000-11-15 Fujisawa Pharmaceutical Co New Polypeptide Compound and a Process for Preparation thereof
DK0669319T3 (da) * 1990-06-27 1999-02-08 Basf Ag O-benzyloximethere og plantebeskyttelsesmidler indeholdende disse forbindelser
JPH04112890A (ja) * 1990-09-04 1992-04-14 Ajinomoto Co Inc 新規チアゾール誘導体及び該誘導体を含有する抗菌剤
EP0486011A3 (en) * 1990-11-16 1992-07-15 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition against pneumocystis carinii
DE4105551A1 (de) * 1991-02-22 1992-08-27 Bayer Ag 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
RU2032677C1 (ru) * 1992-05-05 1995-04-10 Бристоль-Мейерз Сквибб Компани Производные оксазола
CA2100918C (en) * 1992-07-21 1997-01-21 Nobuyuki Hamanaka Oxime derivative
US5512581A (en) 1994-07-18 1996-04-30 Abbott Laboratories Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis
CH689228A5 (de) 1994-10-07 1998-12-31 Novartis Ag Oximether, sowie diese enthaltende Pflanzenschutzmittel.
CA2159938A1 (en) 1994-10-07 1996-04-08 Hiroaki Yanagisawa Oxime derivatives, their preparation and their therapeutic use
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US6022897A (en) 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
WO1996038427A1 (en) * 1995-06-02 1996-12-05 Sankyo Company, Limited Aromatic oxyimino derivatives
US5939442A (en) 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
FR2737893B1 (fr) * 1995-08-16 1997-09-12 Roussel Uclaf Nouvelles cephalosporines comportant en position 7, un radical benzyloxyimino substitue, leur procede et intermediaires de preparation, leur application comme medicaments
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JPH09323929A (ja) 1996-04-02 1997-12-16 Sankyo Co Ltd オキシム誘導体を含有する医薬
ATE252074T1 (de) 1996-04-04 2003-11-15 Sankyo Co Phenylalkylcarbonsäure-derivate
WO1998005331A2 (en) 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
DE69840510D1 (de) 1997-07-24 2009-03-12 Astellas Pharma Inc Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung
JPH11193272A (ja) 1997-10-01 1999-07-21 Sankyo Co Ltd フェニルアルキルカルボン酸誘導体を含有する医薬
AU766831B2 (en) * 1998-05-11 2003-10-23 Takeda Pharmaceutical Company Limited Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

Also Published As

Publication number Publication date
HUP0103714A3 (en) 2003-05-28
IL139470A0 (en) 2001-11-25
PL344002A1 (en) 2001-09-10
NO20005531L (no) 2001-01-05
EP1428531A1 (en) 2004-06-16
CN1300285A (zh) 2001-06-20
HUP0103714A2 (hu) 2002-01-28
LV12606A (lv) 2001-01-20
US6251926B1 (en) 2001-06-26
PT1077957E (pt) 2004-10-29
EP1077957A1 (en) 2001-02-28
DE69919156T2 (de) 2005-11-03
MY123337A (en) 2006-05-31
EP1077957B1 (en) 2004-08-04
JP2000198772A (ja) 2000-07-18
NZ508066A (en) 2003-03-28
AR029876A1 (es) 2003-07-23
RU2213738C2 (ru) 2003-10-10
BR9910371A (pt) 2001-01-09
ES2226377T3 (es) 2005-03-16
ID28699A (id) 2001-06-28
SK16412000A3 (sk) 2001-08-06
CA2331879A1 (en) 1999-11-18
HK1034972A1 (en) 2001-11-09
US6495581B1 (en) 2002-12-17
DE69919156D1 (de) 2004-09-09
WO1999058510A1 (en) 1999-11-18
LV12606B (en) 2001-05-20
AU3629799A (en) 1999-11-29
AU766831B2 (en) 2003-10-23
KR20010021523A (ko) 2001-03-15
CN1148361C (zh) 2004-05-05
KR100388120B1 (ko) 2003-06-18
NO20005531D0 (no) 2000-11-02
CO5040066A1 (es) 2001-05-29
US20030186985A1 (en) 2003-10-02
ATE272625T1 (de) 2004-08-15
PE20000625A1 (es) 2000-07-24
US6924300B2 (en) 2005-08-02

Similar Documents

Publication Publication Date Title
US6495581B1 (en) Oxyiminoalkanoic acid derivatives
US7238716B2 (en) Alkanoic acid derivatives process for their production and use thereof
EP1228067B1 (en) 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
EP1394154A1 (en) Five-membered heterocyclic alkanoic acid derivative
JP4148681B2 (ja) アルカン酸誘導体、その製造法および用途
EP1229026A1 (en) Alkoxyiminoalkanoic acid derivatives
JP3074532B2 (ja) オキシイミノアルカン酸誘導体
MXPA00010576A (en) Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
HK1034972B (en) Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
CZ20004104A3 (cs) Deriváty kyseliny oxyiminoalkanové